Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, single center, open-label, single-arm study designed to evaluate the
efficacy, safety, tolerability, and immunogenicity of AK104 monotherapy in adult subjects
with previously treated recurrent or metastatic high grade neuroendocrine cervical cancer.